Global Oncology/Cancer Drugs Market (Therapeutic Modalities, Cancer Types and Geography) - Size, Share, Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020
Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents expiration of leading drugs along with commercialization of biosimilars are the few factors driving the growth of global oncology drugs market
Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents expiration of leading drugs along with commercialization of biosimilars are the few factors driving the growth of global oncology drugs market
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Global</strong> <strong>Oncology</strong>/<strong>Cancer</strong> <strong>Drugs</strong><br />
<strong>Market</strong><br />
(<strong>Therapeutic</strong> <strong>Modalities</strong>, <strong>Cancer</strong> <strong>Types</strong> <strong>and</strong> <strong>Geography</strong>) -<br />
<strong>Size</strong>, <strong>Share</strong>, <strong>Trends</strong>, <strong>Company</strong> <strong>Profiles</strong>, Dem<strong>and</strong>, <strong>Insights</strong>,<br />
<strong>Analysis</strong>, <strong>Research</strong>, <strong>Report</strong>, <strong>Opportunities</strong>, <strong>Segmentation</strong><br />
<strong>and</strong> <strong>Forecast</strong>, <strong>2013</strong> - <strong>2020</strong><br />
© ALLIED MARKET RESEARCH
Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for<br />
treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various<br />
cancer conditions, growing popularity of advance therapies (biological <strong>and</strong> targeted drug<br />
therapies), patents expiration of leading drugs along with commercialization of biosimilars are<br />
the few factors driving the growth of global oncology drugs market. However, high cost involved<br />
in new drug development coupled with threat of failure <strong>and</strong> adverse effects associated with<br />
cancer drugs therapies would restrain the growth of the market. Commercialization of advanced<br />
therapeutics such as targeted <strong>and</strong> immunotherapies would reduce the negative influence of<br />
restraints <strong>and</strong> fuel the market growth.<br />
The global oncology drugs market is expected to reach at $111.9 billion by <strong>2020</strong>. Patent<br />
expiration of key cancer drugs such as Herceptin, Erbitux, Rituxan <strong>and</strong> Avastin, is expected to<br />
boost the growth of cancer biosimilars market by <strong>2020</strong>. Going further, the biological therapies<br />
are expected to dominate the market by <strong>2020</strong>, due to their high efficacy, target specific action<br />
<strong>and</strong> less toxicity. Blood cancer drugs market was the largest revenue generating segment in <strong>2013</strong><br />
owing to the high cost of drugs (immunotherapies) used for the treatment of blood cancer.<br />
Get Full Access for the <strong>Report</strong> at: http://www.alliedmarketresearch.com/oncology-cancer-drugsmarket<br />
Geographically, North America, dominates the market followed by Europe. North America<br />
accounted for about ~38% share in the overall oncology drugs market in <strong>2013</strong> owing to the heavy<br />
investments by multinational companies in research <strong>and</strong> development of cancer drugs,<br />
particularly immune therapeutics, favorable reimbursement policies, <strong>and</strong> high adoption rate of<br />
immunotherapies. On the other h<strong>and</strong>, Asia-Pacific market would grow at the promising CAGR of<br />
8.7% during the forecast period. Such high growth rate is majorly due to increasing awareness<br />
towards advanced therapies namely immunotherapies <strong>and</strong> increase in per capita healthcare<br />
spending.<br />
Key companies profiled in the report are Roche diagnostics, Novartis AG, Celgene Corporation,<br />
AstraZeneca, Johnson & Johnson, Merck & Co., Eli Lilly & Co. <strong>and</strong> GlaxoSmithKline. Companies<br />
operating in the cancer drugs market focus on several strategies such as collaboration, approval<br />
<strong>and</strong> acquisition.<br />
KEY BENEFITS<br />
<br />
<br />
The report provides the quantitative analysis of the current market <strong>and</strong> estimations through<br />
<strong>2013</strong>-<strong>2020</strong> that assists in identifying the prevailing market opportunities to capitalize on<br />
The report helps in underst<strong>and</strong>ing the strategies adopted by various companies for gaining<br />
market share in the cancer drugs market<br />
© ALLIED MARKET RESEARCH
The report provides comprehensive analysis of factors that drive <strong>and</strong> restrict the growth of the<br />
cancer drugs market<br />
<strong>Market</strong> conditions of cancer drugs market across all geographic regions are comprehensively<br />
analyzed<br />
Competitive intelligence (of leading manufacturers) helps in underst<strong>and</strong>ing the competitive<br />
scenario across the geographies<br />
SWOT analysis of the key market players is provided to illustrate the business strategies adopted<br />
by the companies<br />
MARKET SEGMENTATION<br />
The cancer drugs market is segmented by the therapeutic modalities, cancer types <strong>and</strong><br />
geography.<br />
MARKET BY THERAPEUTIC MODALITIES<br />
<br />
<br />
<br />
<br />
<br />
Chemotherapy<br />
Targeted Therapy<br />
Immunotherapy (Biologic Therapy)<br />
Hormonal Therapy<br />
Others<br />
MARKET BY CANCER TYPES<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Blood <strong>Cancer</strong><br />
Breast <strong>Cancer</strong><br />
Gastrointestinal <strong>Cancer</strong><br />
Prostate <strong>Cancer</strong><br />
Respiratory/Lung <strong>Cancer</strong><br />
Skin <strong>Cancer</strong><br />
Other <strong>Cancer</strong>s<br />
MARKET BY GEOGRAPHY<br />
<br />
<br />
North America<br />
United States<br />
Canada<br />
Mexico<br />
Europe<br />
Germany<br />
© ALLIED MARKET RESEARCH
France<br />
United Kingdom<br />
Others<br />
Asia-Pacific<br />
India<br />
China<br />
Japan<br />
Australia<br />
Others<br />
LAMEA<br />
GCC (Gulf Corporation Council)<br />
Others<br />
About Us:<br />
Allied <strong>Market</strong> <strong>Research</strong> (AMR) is a full-service market research <strong>and</strong> business-consulting wing of<br />
Allied Analytics LLP based in Portl<strong>and</strong>, Oregon. Allied <strong>Market</strong> <strong>Research</strong> provides global enterprises<br />
as well as medium <strong>and</strong> small businesses with unmatched quality of "<strong>Market</strong> <strong>Research</strong> <strong>Report</strong>s"<br />
<strong>and</strong> "Business Intelligence Solutions". AMR has a targeted view to provide business insights <strong>and</strong><br />
consulting to assist its clients to make strategic business decisions <strong>and</strong> achieve sustainable growth<br />
in their respective market domain.<br />
We are in professional corporate relations with various companies <strong>and</strong> this helps us in digging<br />
out market data that helps us generate accurate research data tables <strong>and</strong> confirms utmost<br />
accuracy in our market forecasting. Each <strong>and</strong> every data presented in the reports published by us<br />
is extracted through primary interviews with top officials from leading companies of domain<br />
concerned. Our secondary data procurement methodology includes deep online <strong>and</strong> offline<br />
research <strong>and</strong> discussion with knowledgeable professionals <strong>and</strong> analysts in the industry.<br />
Contact Us:<br />
Cathy Viber<br />
5933 NE Win Sivers Drive<br />
#205, Portl<strong>and</strong>, OR 97220<br />
United States.<br />
Direct: +1(503)505-6949<br />
Toll Free: +1(855)711-1555 (U.S. & Canada)<br />
Fax: +1(855)550-5975<br />
Email: query@alliedmarketresearch.com<br />
Web: http://www.alliedmarketresearch.com/<br />
© ALLIED MARKET RESEARCH
© ALLIED MARKET RESEARCH
© ALLIED MARKET RESEARCH
Change language